Shu Li1, Zhengfu Fan1, Zhiwei Fang1, Jiayong Liu1, Chujie Bai1, Ruifeng Xue1, Lu Zhang1, Tian Gao1. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumors, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Abstract
OBJECTIVE: To assess the efficacy of conservative chemotherapy for inoperable desmoid tumor (DT) and analyze the prognostic factors. METHODS: From November 2008 to April 2016, 71 patients of inoperable DT were treated with vinorelbine and low-dose methotrexate in the Department of Bone and Soft Tissue Tumors, Peking University Cancer Hospital & Institute, and enrolled in this retrospective study. The chemotherapy duration is one year. The efficacy of chemotherapy and the prognosis were observed. RESULTS: Of the 71 patients, 55% were female. Age of onset varied from 1 to 47 years, and the median age was 14 years. Only 11 (15.5%) cases suffered primary tumor. The distribution of the site of tumors was: 31 (43.7%) in the trunk, 36 (50.7%) in the limbs, and 4 (5.6%) in the peritoneal and pelvic cavity. The size of tumor (the maximum diameter) differed from 2 to 37 cm with a mean of 9.3 cm. The median follow-up duration was 28 (range, 6-87) months. Common side effects included: nausea and vomiting, liver injury, bone marrow suppression and oral ulcers. When the chemotherapy finished, 1 (1.4%) case achieved complete response, 24 (33.8%) achieved partial response, 37 (52.1%) achieved stable disease and 9 (12.7%) had progressive disease. The overall response rate was 87.3%. The progression-free survival (PFS) of the participants were from 6 to 87 months, and the 2-, 3- and 5-year PFS was 79.9%, 68.4% and 36.3%, respectively. No significant difference was identified in PFS in subgroups of gender, age of onset, age of chemotherapy, tumor site and tumor size. CONCLUSIONS: For recurrent, inoperable and progressive DT, enough course of chemotherapy with vinorelbine combined with low-dose methotrexate was an optional choice for local control.
OBJECTIVE: To assess the efficacy of conservative chemotherapy for inoperable desmoid tumor (DT) and analyze the prognostic factors. METHODS: From November 2008 to April 2016, 71 patients of inoperable DT were treated with vinorelbine and low-dose methotrexate in the Department of Bone and Soft Tissue Tumors, Peking University Cancer Hospital & Institute, and enrolled in this retrospective study. The chemotherapy duration is one year. The efficacy of chemotherapy and the prognosis were observed. RESULTS: Of the 71 patients, 55% were female. Age of onset varied from 1 to 47 years, and the median age was 14 years. Only 11 (15.5%) cases suffered primary tumor. The distribution of the site of tumors was: 31 (43.7%) in the trunk, 36 (50.7%) in the limbs, and 4 (5.6%) in the peritoneal and pelvic cavity. The size of tumor (the maximum diameter) differed from 2 to 37 cm with a mean of 9.3 cm. The median follow-up duration was 28 (range, 6-87) months. Common side effects included: nausea and vomiting, liver injury, bone marrow suppression and oral ulcers. When the chemotherapy finished, 1 (1.4%) case achieved complete response, 24 (33.8%) achieved partial response, 37 (52.1%) achieved stable disease and 9 (12.7%) had progressive disease. The overall response rate was 87.3%. The progression-free survival (PFS) of the participants were from 6 to 87 months, and the 2-, 3- and 5-year PFS was 79.9%, 68.4% and 36.3%, respectively. No significant difference was identified in PFS in subgroups of gender, age of onset, age of chemotherapy, tumor site and tumor size. CONCLUSIONS: For recurrent, inoperable and progressive DT, enough course of chemotherapy with vinorelbine combined with low-dose methotrexate was an optional choice for local control.
Authors: G Pignatti; G Barbanti-Bròdano; D Ferrari; F Gherlinzoni; F Bertoni; P Bacchini; E Barbieri; A Giunti; M Campanacci Journal: Clin Orthop Relat Res Date: 2000-06 Impact factor: 4.176
Authors: Peter D Peng; Omar Hyder; Michael N Mavros; Ryan Turley; Ryan Groeschl; Amin Firoozmand; Michael Lidsky; Joseph M Herman; Michael Choti; Nita Ahuja; Robert Anders; Daniel G Blazer; T Clark Gamblin; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2012-09-13 Impact factor: 5.344
Authors: A Azzarelli; A Gronchi; R Bertulli; J D Tesoro; D Baratti; E Pennacchioli; P Dileo; A Rasponi; A Ferrari; S Pilotti; P G Casali Journal: Cancer Date: 2001-09-01 Impact factor: 6.860
Authors: A Gronchi; P G Casali; L Mariani; S Lo Vullo; M Colecchia; L Lozza; R Bertulli; M Fiore; P Olmi; M Santinami; J Rosai Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Jae-Cheol Jo; Yong Sang Hong; Kyu-Pyo Kim; Jae-Lyun Lee; Jeeyun Lee; Young Suk Park; Sun Young Kim; Jin-Sook Ryu; Jong-Seok Lee; Tae Won Kim Journal: Invest New Drugs Date: 2014-01-16 Impact factor: 3.850
Authors: Katrina M Ingley; Sally M Burtenshaw; Nicole C Theobalds; Lawrence M White; Martin E Blackstein; Rebecca A Gladdy; Seng Thipphavong; Abha A Gupta Journal: Cancer Med Date: 2019-07-13 Impact factor: 4.452
Authors: Spyridon Gennatas; Florence Chamberlain; Alannah Smrke; James Stewart; Andrew Hayes; Lorna Roden; Christina Messiou; Jie-Ying Kowa; Anna Estival; Dharmisha Chauhan; Khin Thway; Cyril Fisher; Winette T A van der Graaf; Robin L Jones; Charlotte Benson Journal: Oncologist Date: 2020-10-02